The efficacy of intralesional corticosteroid injections for patients with keloids and hypertrophic scars has been well recognised. TAC is one of the most commonly used corticosteroids. The dose and treatment intervals have a range of 10–40 mg/ml which is given atintermission of 2–6 weeks for several months or until the scar is evened out [17, 32]. Although the fact that intralesional TAC has shown a 50%-100% success rate in different studies, the outcome has not been satisfactory and with numerous unpleasant effects, including skin atrophy, telangiectasias, and altered pigmentation at the injection site [33, 34]